These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30585351)

  • 1. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
    Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences.
    Montico F; Kido LA; San Martin R; Rowley DR; Cagnon VH
    Prostate; 2015 Oct; 75(14):1643-61. PubMed ID: 26184673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
    Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
    J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
    da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
    J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroidal hormone and morphological responses in the prostate anterior lobe in different cancer grades after Celecoxib and Goniothalamin treatments in TRAMP mice.
    Silva RS; Kido LA; Montico F; Vendramini-Costa DB; Pilli RA; Cagnon VHA
    Cell Biol Int; 2018 Aug; 42(8):1006-1020. PubMed ID: 29603508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
    Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
    Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
    da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
    Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
    Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
    Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
    Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
    Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
    Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
    Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
    Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
    Alves LF; da Silva RF; Cagnon VHA
    Tissue Cell; 2018 Feb; 50():96-103. PubMed ID: 29429524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
    Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
    Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
    Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
    Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
    Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
    Kido LA; Montico F; Vendramini-Costa DB; Pilli RA; Cagnon VHA
    Prostate; 2017 Jun; 77(8):838-848. PubMed ID: 28191652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.
    Sehgal PD; Bauman TM; Nicholson TM; Vellky JE; Ricke EA; Tang W; Xu W; Huang W; Ricke WA
    Hum Pathol; 2019 Jul; 89():99-108. PubMed ID: 31054895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.